

**Amendments to the claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (original): A composition suitable for the treatment or prophylaxis of COPD and other acute or chronic diseases in a mammal, especially a human being, comprising at least one of glutamate, other than mono sodium glutamate, and a precursor of glutamate selected from the group consisting of leucine, valine, isoleucine, and a keto acid thereof, in a daily dose for said mammal of at least 6 grams of the total of said glutamate and precursor forms thereof.
2. (original): A composition as claimed in claim 1 comprising at least one of glutamate, other than mono sodium glutamate, and a precursor of glutamate selected from the group consisting of leucine, valine, isoleucine, and a keto acid thereof, in a daily dose for said mammal in a range of between 9 and 20 grams of the total of said glutamate and precursor forms thereof.
3. (currently amended): A composition as claimed in claim 1 ~~or claim 2~~ which is a dietary food supplement where the amount of said glutamate or said precursor form thereof is subdivided in dosages of up to 3 grams, for regular administration to achieve continuously increasing glutamate level.
4. (currently amended): A composition as claimed in claim 1 ~~or claim 2~~ which is a pharmaceutical composition where the amount of said glutamate or said precursor form thereof is subdivided in unit dosages of up to 3 grams, for regular administration to achieve continuously increasing glutamate level, the pharmaceutical composition further comprising a pharmaceutical acceptable carrier.

5. (currently amended): A method of preparing a unit dose medicament, comprising providing ~~Use of~~ at least one of glutamate, other than mono sodium glutamate, and a precursor of glutamate selected from the group consisting of leucine, valine, isoleucine, and a keto acid thereof, in the ~~preparation of a~~ medicament for the treatment or prophylaxis of COPD and other acute or chronic diseases in a mammal, especially a human being, wherein the medicament is formulated ~~in a unit dose form~~ to achieve a daily dose of at least 6 grams of the active ingredient of the medicament.

6. (currently amended): A method ~~Use~~ as claimed in claim 5, wherein the medicament is formulated in a unit dose form to achieve a daily dose in a range of between 9 and 20 grams of the active ingredient of the medicament.

7. (currently amended): A pharmaceutical composition as claimed in claim 4, ~~or the use as claimed in claim 5 or claim 6,~~ which is formulated for oral or parenteral administration.

8. (currently amended): A pharmaceutical composition as claimed in claim 4, ~~or the use as claimed in claim 5 or claim 6,~~ which is formulated to achieve a continuously increasing glutamate level.

9. (currently amended): A method ~~Use~~ as claimed in ~~any one claims~~ claim 5 ~~to 8~~, wherein the medicament additionally contains one or more substances selected from the group of stimulants, hormones, analogues of such hormones, phyto-hormones, analogues of such phyto-hormones, and anti-oxidants.

10. (original): A method of preventing or treating COPD and other acute or chronic diseases in a mammal, in particular a human, which comprises administering to said mammal a therapeutically effective amount of at least one of glutamate, other than mono sodium glutamate, and a precursor of glutamate selected from the group consisting of leucine, valine, isoleucine, and a keto acid thereof.

11. (currently amended): A method of preparing a food supplement or a prophylactic composition, comprising providing ~~Use of~~ at least one of glutamate, other than mono sodium glutamate, and a precursor of glutamate selected from the group consisting of leucine, valine, isoleucine, and a keto acid thereof, in the ~~preparation of~~ food supplement or ~~[[a]]~~ prophylactic composition to restore or increase the glutamate level in the body, in particular the muscles, of an individual.